Fulvimac 250mg Injection

Fulvimac 250mg injection contains the active substance Fulvestrant. It is an antineoplastic drug that belongs to the class estrogen receptor antagonist. Estrogen, a type of female sex hormone, can sometimes be involved in the growth of breast cancer. This medicine is used alone to treat postmenopausal women with a certain type of breast cancer called estrogen receptor-positive breast cancer that is locally advanced or spread to other parts of the body. It is also indicated in combination with other anti-cancer medication to treat women with certain types of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, which is locally advanced or spread to other parts of the body. Do not take this injection if you are allergic to fulvestrant or any other ingredients of this medicine, pregnant or breastfeeding, or have severe liver problems. Before initiating the treatment, inform your physician if you have kidney or liver problems, bone diseases, bleeding disorders, and heart diseases. Fulvimac 250mg injection is not indicated in children and adolescents under 18 years. Report to your physician if you have allergic reactions, including swelling of the face, lips, tongue, or throat, after administering this injection. Common side effects of Fulvimac 250mg injection are pain or inflammation at the site of injection, abnormal levels of liver enzymes, nausea, headache, cough, weakness or tiredness, joint and muscle pain, hot flashes, hair loss, and skin rash. Your doctor may advise you to take certain blood tests while receiving this injection. This injection may increase your risk of bleeding and liver failure. Female patients of reproductive potential should use effective contraception during treatment with this injection and for two years after the last dose.